Trident Lifeline Ltd

Trident Lifeline has shown significant growth over the past four years, with net sales increasing from 21.77 Cr in Mar'22 to 86.96 Cr in Mar'25, and profit after tax rising from 3.95 Cr to 10.49 Cr. However, cash flow from operating activities has been negative, indicating challenges despite overall revenue and profitability growth.

Trident Lifeline has shown significant growth in net sales, operating income, and profitability from Mar'22 to Mar'25, with net sales increasing from 21.77 Cr to 86.96 Cr and profit after tax rising from 3.95 Cr to 10.49 Cr. However, cash flow from operations has declined, with a cash outflow of 10.00 Cr in Mar'25.

As of 11-Nov, Trident Lifeline Ltd's stock price is at Rs 318.00, up 5.74%, and nearing its 52-week high. The stock shows strong performance metrics and increasing institutional interest, indicating a positive outlook despite a recent decline in investor participation.

The next results date for Trident Lifeline is 11 November 2025.

As of 03-Nov, Trident Lifeline Ltd's stock price is Rs 296.50, down 1.17%. Despite a year-to-date increase of 5.89%, the stock has underperformed recently, with mixed signals from moving averages and decreased investor participation, reflecting short-term challenges amid a generally cautious market sentiment.

As of October 30, 2025, Trident Lifeline is considered very expensive with a PE ratio of 23.10 and an EV to EBIT ratio of 24.99, indicating overvaluation compared to peers like Sun Pharma and Cipla, despite a year-to-date return of 13.93%.

As of 30-Oct, Trident Lifeline Ltd's stock price is at Rs 319.00, up 9.98%, and has outperformed the Sensex year-to-date. However, a significant drop in delivery volume raises concerns about the sustainability of this upward trend.

As of October 28, 2025, Trident Lifeline is considered expensive with a PE Ratio of 21.00, indicating it is overvalued compared to peers like Sun Pharma and Divi's Lab, despite a strong 3-year return of 97.65%, its recent performance has lagged behind the Sensex.

As of 28-Oct, Trident Lifeline Ltd's stock price is Rs 290.05, down 2.67%, and has underperformed its sector and the benchmark Sensex. Despite a year-to-date gain of 3.59%, the stock has seen a significant drop in delivery volume and has lagged behind market trends.

As of 17-Oct, Trident Lifeline Ltd's stock price is rising to Rs 308.80, reflecting a 2.93% increase and strong performance relative to its sector and the broader market. The stock has shown consistent gains, positive long-term growth, and increased institutional investment, indicating strong investor confidence.

As of October 16, 2025, Trident Lifeline is considered very expensive with a PE Ratio of 21.65 and an EV to EBITDA of 18.24, despite outperforming the Sensex with an 8.91% return over the past year, indicating overvaluation compared to peers like Sun Pharma and Cipla.

As of October 14, 2025, Trident Lifeline is considered overvalued with a valuation grade of expensive, a PE ratio of 21.14, and a PEG ratio of 0.25, indicating potential growth, but it still does not justify its price compared to peers like Sun Pharma and Divi's Lab.

As of September 29, 2025, Trident Lifeline is considered overvalued with a valuation grade of expensive, a PE ratio of 20.27, and underperformance against the Sensex, indicating concerns about its growth and returns compared to peers.

As of September 26, 2025, Trident Lifeline is considered very expensive with a PE ratio of 21.47 and other high valuation metrics, despite a recent positive short-term performance, indicating significant overvaluation compared to its peers.

As of September 26, 2025, Trident Lifeline is considered very expensive with a PE ratio of 21.47 and an EV to EBITDA of 16.28, indicating overvaluation compared to peers like Sun Pharma and Cipla, despite a year-to-date return of 5.89%.

As of September 26, 2025, Trident Lifeline is considered very expensive and overvalued with a PE ratio of 21.47, an EV to EBITDA of 16.28, and a Price to Book Value of 6.88, especially when compared to peers like Sun Pharma and Cipla, despite a recent positive performance against the Sensex.

As of September 24, 2025, Trident Lifeline is considered overvalued with a valuation grade of expensive, reflected by a PE ratio of 21.02 and lower ROCE compared to peers, indicating it may not be a compelling investment despite recent stock performance.

As of 24-Sep, Trident Lifeline Ltd's stock price is at 290.25, down 2.5% today, but has shown positive trends over the past week and month. Despite current declines, strong financial metrics and increased institutional interest suggest potential for recovery.